Post-ERCP pancreatitis
Conditions
Interventions
Non-administration of Nafamostat Mesilate group
Nafamostat Mesilate administered before ERCP group.
Nafamostat Mesilate administered after ERCP group.
Sponsors
Dept. of Gastroenterology, Kitasato University East Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are planned ERCP with hospitalization. 1) Patients with agreement of this clinical study. 2) Aged 20 or over.
Exclusion criteria
Exclusion criteria: 1) Patients without informed consent. 2) Patients who are not possible to communicate by mental disorder or disturbance of consciousness. 3) Patients who are pregnant or during pregnancy can not be ruled out. 4) Acute pancreatitis cases. 5) Patients with severe cardiopulmonary disease. 6) Patients who are received protease inhibitor within a week. 7) Patients with a history of allergy to iodine-based contrast agent and Nafamostat Mesilate. 8) Patients who are expected to be difficult to observe duodenal papilla endoscopically. 9) Endoscopic papillectomy cases. 10) Patients with Billroth-II and total gastrectomy. 11) Patients after treatment duodenal papilla EST, such as EPBD. 12) Patients who are judged inappropriate by medical examiner.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and severity of post-ERCP pancreatitis in the non-administration and the administration of Nafamostat Mesilate group. | — |
Countries
Japan
Contacts
Public ContactHiroshi Imaizumi
Kitasato University Hospital Dept. of Gastroenterology
Outcome results
None listed